MIM
ENFN

MetLife Investment Management’s Enfusion, Inc. ENFN Stock Holding History

MetLife Investment Management’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,616
Closed -$375K – 2945
2025
Q1 		$375K Sell
33,616
-169
-0.5% -$1.87K ﹤0.01% 1864
2024
Q4 		$348K Buy
33,785
+4,993
+17% +$48.3K ﹤0.01% 1991
2024
Q3 		$273K Hold
28,792
– – ﹤0.01% 2130
2024
Q2 		$245K Buy
28,792
+7,996
+38% +$73.2K ﹤0.01% 2123
2024
Q1 		$192K Hold
20,796
– – ﹤0.01% 2229
2023
Q4 		$202K Hold
20,796
– – ﹤0.01% 2238
2023
Q3 		$187K Buy
20,796
+6,590
+46% +$62.6K ﹤0.01% 2255
2023
Q2 		$159K Hold
14,206
– – ﹤0.01% 2404
2023
Q1 		$149K Hold
14,206
– – ﹤0.01% 2381
2022
Q4 		$137K Hold
14,206
– – ﹤0.01% 2459
2022
Q3 		$175K Hold
14,206
– – ﹤0.01% 2384
2022
Q2 		$145K Hold
14,206
– – ﹤0.01% 2515
2022
Q1 		$181K Buy
14,206
+5,065
+55% +$77.4K ﹤0.01% 2410
2021
Q4 		$191K Buy
+9,141
New +$185K ﹤0.01% 2074

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

MetLife Investment Management's ENFN Position: Q2 2025 in Review

MetLife Investment Management sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 33,616 shares — an estimated $375K sold.

MetLife Investment Management first reported a position in ENFN in Q4 2021 and held it in 14 quarters. The position peaked at $375K in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • MetLife Investment Management reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 33,616 Enfusion, Inc. shares in Q2 2025, an estimated $375K.
  • MetLife Investment Management first reported a position in Enfusion, Inc. in Q4 2021 and held it in 14 quarters.
  • MetLife Investment Management's Enfusion, Inc. position peaked at $375K in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.